NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Celcuity Inc. Common Stock (CELC) Stock Analysis

Celcuity Inc. Common Stock (CELC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CELC

$61.56

+$1.56 (+2.60%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CELC with… →

CELC Key Statistics

As of Oct 21, 2026
Trading
Open
$60.42
Previous Close
$60.00
Day's Range
60.23–62.81
52-Week Range
45.03–151.02
Volume
1.59M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.11
Valuation
Market Cap
$3.09B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.31
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$177.04M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.93M
1-Year Return
−6.02%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CELC closed at $61.56, −6.02% over 1 year.

Celcuity Inc. Common Stock (CELC) has a market capitalization of $3.09B.

In fiscal 2025, CELC reported revenue of $0.00.

CELC Stock Return by Calendar Year

Celcuity Inc. Common Stock (CELC) return since Sep 2017: what $10,000 became

1 year
$10,000 $9,398
−6.02%
5 years
$10,000 $35,017
+250.17%
Since Sep 2017
$10,000 $43,079
+330.79%

If you had invested $10,000 in Celcuity Inc. Common Stock (CELC) at the close on September 20, 2017, the earliest close on record here, it would have been worth $43,079 at the close on October 21, 2026: +330.79% in total, +17.44% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−38.28%
2025+661.96%
2024−10.16%
2023+4.00%
2022+6.22%
2021+44.00%
2020−13.91%
2019−55.65%
2018+26.60%
2017 (partial year)+32.61%

As of October 21, 2026.

CELC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$177.04M—
2024$0.00−$111.78M—
2023$0.00−$63.78M—
2022$0.00−$40.37M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$172.19M−$177.04M—
2024$0.00—−$113.27M−$111.78M—
2023$0.00—−$66.23M−$63.78M—
2022$0.00—−$39.39M−$40.37M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Celcuity Inc. Common Stock (CELC) carries a market capitalisation of $3.09B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 155 employees.

CELC last closed at $61.56 on October 21, 2026. That is +$1.56 (+2.60%) against the previous close. Over the past 52 weeks the price has ranged from $45.03 to $151.02. The latest close sits 36.71% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $177.04M. Earnings per share on a trailing basis come to −4.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.11. Annualized volatility over the trailing 9 years is 90.78%. The trailing one-year total return is −6.02%. Across 5 years the annualized return works out at +28.49%.

Growth & Income

The record shows no dividend for CELC.

So far in 2026 the total return is −38.28%. The strongest complete calendar year on file is 2025 at +661.96%; the weakest is 2019 at −55.65%. Of the 8 complete calendar years on file, 5 finished higher.

Peer Comparison

Celcuity Inc. Common Stock (CELC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Celcuity Inc. Common Stock CELC $3.09B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Celcuity Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Celcuity Inc. Common Stock

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Visit website →